Radiodermatitis Market

Global Radiodermatitis Market Size (2024 to 2029)

The global market size for radiodermatitis is expected to grow at a CAGR of 5.22% from 2024 to 2029 and be worth USD 772.15 million by 2029 from USD 598.70 million in 2024.

Radiodermatitis, also known as radiation dermatitis and x-ray dermatitis. Radiodermatitis is a side effect of ionizing radiation delivered to the skin during cancer treatment resulting from nuclear attacks and disasters. Radiodermatitis, including erythema, dry desquamation, and moist desquamation, are some forms developed when cancer patients receive radiation therapy. These radiation skin reactions result in many complications, including delays in treatment, loss of cosmetic appeal, and reduced quality of life. 95% of the patients who receive Radiation for cancer treatment are affected by radiation dermatitis, with around 85% of patients having moderate-to-severe cutaneous conditions. Redness, itching, peeling, flaking, blister, and soreness are the common symptoms of this disease. This Radiation can be very painful for cancer patients. Different products and solutions are available, and newer ones are constantly entering the market. Local treatments such as corticosteroids, hydrophilic creams, topical antibiotics, oral corticosteroids, analgesics, anti-inflammatory drugs, and dressings are primarily used to treat radiodermatitis. Four levels were included in Acute radiodermatitis grade 1 -mild erythema, grade 2 -dry desquamation, grade 3 -severe moist desquamation, and grade 4 -life-threatening and chronic.

Global Radiodermatitis Market Drivers:

The increasing rate of various cancers and the rising number of people with diabetes are majorly propelling the radiodermatitis market.The incidence of breast and head, and neck cancer is significantly increasing. All these cancers can be treated with radiation. Therefore, radiation-induced dermatitis is more likely to affect patients with certain cancers; the radiodermatitis market is projected to grow due to an increase in cancer cases and unhealthy lifestyle choices. In addition, people suffering from diabetes and obesity are increasing rapidly at risk of cancer. This is another factor likely to drive the need for radiation therapy to boost radiodermatitis drugs. In 2018, as per the CDC (Centers for Disease Control), diabetes cases had risen to 34.2 million, which is likely to grow globally by 2030. This indicates that a larger pool of patients is expected to develop cancer and would have a higher chance of radiation-induced skin damage due to co-morbid conditions.

An increase in the number of older people, a growing number of public and private healthcare organizations, awareness about radiodermatitis management and treatment, and a rise in the desire for the abolition of radiation therapy-related adverse effects are further anticipated to boost the growth rate of the radiodermatitis market. In addition, the increasing adoption of online pharmacies in the radiodermatitis market may create favorable conditions for investors worldwide. Online pharmacy is a growing platform that plays a significant role in the sales of radiodermatitis drugs. 

Customers can order radiodermatitis medicines by using a computer or smartphone phone. This provides an opportunity for the radiodermatitis market in the coming years. To expand their product portfolio, leading players focus on advanced products.

Global Radiodermatitis Market Restraints:

Lack of awareness about chronic and acute Radiodermatitis and the high cost of radiodermatitis products will restrain the growth of the radiodermatitis market. In addition, the side effects of radiation therapy are the major challenge faced by the radiodermatitis market.

Impact of COVID-19 on the global radiodermatitis market:

The outbreak of coronavirus has affected several industries in the world. Lockdowns resulted in the closure of factories and industries, disrupting many industries' supply and distribution channels. The current coronavirus pandemic has slightly impacted the radiodermatitis market and has a moderate impact on the radiodermatitis market. Patients with cancer are at high-risk risk during the pandemic because they frequently need hospital visits for radiation therapy doses. Italian Association of Radiotherapy and Clinical Oncology (AIRO), a leading cancer institution in June 2020, reported that radiotherapy has proven to be the safest and most appropriate cancer treatment during the COVID-19 outbreak. Radiotherapy is a common side-effect of Radiodermatitis, which can cause damage to the skin cells of the patient. After the post-pandemic, the demand for radiodermatitis products may foresee a positive impact on the global market.

REPORT COVERAGE:

This research report on the global radiodermatitis market has been segmented and sub-segmented based on product, distribution channel & region.

Global Radiodermatitis Market - By Product:

• Topical
  • Corticosteroids
  • Hydrophilic Creams
  • Topical Antibiotics
  • Others
• Oral Drugs
• Dressings
  • Hydrogel and Hydrocolloid Dressings
  • No Sting Barrier Film
  • Honey Impregnated Gauze
  • Silicone Coated

Based on the product, the topical segment had the highest share of the global radiodermatitis market in 2022. Topical products reduce the risk of microbial transmission and protect the skin against harsh agents. Corticosteroids, hydrophilic creams, and topical antibiotics are some of the significant products in this segment. The Corticosteroids sub-segment accounted for the largest share amongst topical agents as a consequence of being considered a standard in the treatment of inflammatory skin conditions, which encourages their adoption for the treatment of Radiodermatitis. 

Global Radiodermatitis Market – By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Based on the distribution channel, the hospital pharmacy segment led the radiodermatitis market in 2022. This is due to the factors such as the increasing geriatric population and hospital infrastructure developments. Hence, the demand for radiodermatitis medicines in the hospital pharmacy segment is expected to grow substantially, which may further accelerate the market in the forecasted years.

Global Radiodermatitis Market – By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Geographically, the Asia-Pacific region dominated the radiodermatitis market worldwide in 2022. This is due to an increase in disposable income, expansion of biotechnology & pharmaceutical companies, and increasing awareness among Asian consumers regarding enhancing the quality of life, increase in the prevalence of cancer cases, huge adoption of advanced healthcare products, and growing investment in healthcare infrastructure. Additionally, reimbursement policies and rising demand for radiation therapy reimbursements, along with a rise in demand for radiation therapy, specifically in China, Japan, and India, may drive the Asia-Pacific radiodermatitis market in the coming years. Furthermore, with a favorable government, an increase in outsourcing by industrialized nations, rising obesity rates, demand for radiation dermatitis products, and the presence of a prominent cancer patient pool, India is expected to see considerable growth in the following years, which are driving forces for this region's growth.

On the other hand, the North American radiodermatitis market is expected to account for a substantial share of the global market during the forecast period due to advanced product development and the increasing incidence of cancer-causing diseases. In addition, the US-dominated North America is due to the growing prevalence of cancer. According to data reported by the American Society for Radiation Oncology, approximately 95% of patients receiving radiation therapy suffer from some degree of Radiodermatitis, whereas 85% of the total patient base experience severe to moderate Radiodermatitis needs emergency care. This is expected to drive the utilization of radiodermatitis products globally.

According to WHO, it is increasing tobacco consumption and alcohol consumption account for 40% of cancer cases in European countries. Amongst which 20% of cancer leads to deaths in the European region. This factor is forecasted to drive the Europe radiodermatitis market during the forecast period.

TOP COMPANIES IN THIS MARKET:

Key players in the Radiodermatitis market include 3M Company, Smith & Nephew, Acelity (3M Company), Derma Sciences (Integra LifeSciences Holdings Corporation), Molnlycke Health Care (Investor AB), ConvaTec, Stratpharma, LETI Pharma, BMG Pharma, and Alliqua BioMedical.

RECENT MARKET DEVELOPMENTS:

• In 2021, FRIULIA invested €2 MILLION In BMG Pharma. The investment is mainly to support the Business Plan that includes about €9 million in investments over the next three years in clinical research and trials.
• In 2021, a leading global medical technology company, Integra LifeSciences Holdings Corporation, announced that it had completed the previously-disclosed acquisition of ACell, Inc.
• In 2019, Kannalife, Inc., a biopharmaceutical company focusing on discovering and developing cannabis medicines, announced the filing of a new US Patent for its patented and revolutionary CBD-like compounds to treat radiation dermatitis (RD) and other skin conditions.

• In 2019, Integra LifeSciences Holdings Corporation announced the acquisition of Rebound Therapeutics.